Viking TherapeuticsNASDAQ: VKTX

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.

Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell the news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025.

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.

SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences.  Details of the company's participation are as follows: Truist Healthcare Conference Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: November 7, 2024 Fireside Chat Timing: 12:30 – 1:00 p.m.

The U.S. presidential election will be held on November 5, 2024, but there's another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Society will hold its annual meeting, ObesityWeek 2024.

It might not be too late to get in on the party.